US 12,129,243 B2
Modulators of Mas-related G-protein receptor X2 and related products and methods
Marion Lanier, San Diego, CA (US); Marcus Boehm, San Diego, CA (US); Liming Huang, San Diego, CA (US); Esther Martinborough, San Diego, CA (US); Marcos Sainz, San Diego, CA (US); Brandon Selfridge, San Diego, CA (US); and Adam Yeager, San Diego, CA (US)
Assigned to Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed by Escient Pharmaceuticals, Inc., San Diego, CA (US)
Filed on Nov. 17, 2023, as Appl. No. 18/513,400.
Application 18/513,400 is a continuation of application No. 18/192,313, filed on Mar. 29, 2023.
Claims priority of provisional application 63/476,920, filed on Dec. 22, 2022.
Claims priority of provisional application 63/325,611, filed on Mar. 30, 2022.
Prior Publication US 2024/0124415 A1, Apr. 18, 2024
Int. Cl. C07D 471/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 498/04 (2006.01)
CPC C07D 401/12 (2013.01) [C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01)] 11 Claims
 
1. A compound having the following structure, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof:
 
Structure Cpd No.
 
 

OG Complex Work Unit Chemistry
 Ex. 1